Announcement on the Receipt of CEP Certificate for Gadobutrol Chemical API from the European Medicines Agency

Beilu Pharmaceutical Co., Ltd.·May 28, 2026·2 pages

✨ AI Summary

Beijing Beilu Pharmaceutical Co., Ltd. has received a CEP certificate for its gadobutrol chemical API from the European Medicines Agency, effective May 27, 2026. This certification allows the company to sell the product in the EU market, enhancing its international standing. The gadobutrol injection is included in the national medical insurance catalog. Investors are advised to consider potential risks associated with international operations.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Beijing Beilu Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.

Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the European Pharmacopoeia Certificate of Suitability (CEP) for gadobutrol chemical API issued by the European Medicines Agency (EDQM). The relevant details are announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.